Solomon Langermann

Solomon Langermann is an Assistant Professor in Medical Oncology and Hematology at Yale School of Medicine. His research focuses on cancer immunotherapy, immune checkpoint pathways, and tumor immunity mechanisms. He has contributed to studies on combination therapies involving anti-cancer agents like NC410 and pembrolizumab, targeting pathways such as FLRT3-UNC5B and BCAM. His work spans preclinical models and clinical trials in colorectal, ovarian, and hematologic cancers. Key collaborators include David Rimm, Kurt Schalper, and Frederick Wilson. Langermann's studies explore therapeutic targets to enhance T-cell function and overcome tumor immune evasion.